SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Roche Robert P Jr. – ‘4’ for 5/24/22 re: Antares Pharma, Inc.

On:  Thursday, 5/26/22, at 5:30pm ET   ·   For:  5/24/22   ·   Accession #:  899243-22-19797   ·   File #:  1-32302

Previous ‘4’:  ‘4’ on 6/14/21 for 6/10/21   ·   Latest ‘4’:  This Filing

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/26/22  Roche Robert P Jr.                4                      1:21K  Antares Pharma, Inc.              Donnelley Fin’l S… 06/FA

Statement of Changes in Beneficial Ownership of Securities by an Insider   —   Form 4   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 4           Form 4 Submission -- doc4.xml/3.6                   HTML      3K


        

This ‘4’ Document is an XML Data File that may be rendered in various formats:

  Form 4    –   Plain Text   –  SEC Website  –  EDGAR System  –    XML Data    –  <?xml?> File
 
 
Plain Text rendering:  Form 4 Submission
 
                                                                                                                                                                                
Ownership Document
 
Schema Version:  X0306
Document Type:  4
Period of Report:  5/24/22
Not Subject to Section 16:  1
Issuer:
Issuer CIK:  1016169
Issuer Name:  ANTARES PHARMA, INC.
Issuer Trading Symbol:  ATRS
Reporting Owner:
Reporting Owner ID:
Owner CIK:  1210193
Owner Name:  ROCHE ROBERT P JR
Reporting Owner Address:
Owner Street 1:  C/O ANTARES PHARMA, INC.
Owner Street 2:  100 PRINCETON SOUTH, SUITE 300
Owner City:  EWING
Owner State:  NJ
Owner ZIP Code:  08628
Owner State Description:
Reporting Owner Relationship:
Is Director?  Yes
Is Officer?  No
Is Ten Percent Owner?  No
Is Other?  No
Non-Derivative Table:
Non-Derivative Transaction:
Security Title:
Value:  Common Stock
Transaction Date:
Value:  5/24/22
Deemed Execution Date:
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  D
Equity Swap Involved?  No
Footnote ID:  F1
Footnote ID:  F2
Transaction Timeliness:
Value:
Transaction Amounts:
Transaction Shares:
Value:  118,392
Transaction Price Per Share:
Value:  5.60
Transaction Acquired-Disposed Code:
Value:  D
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  0
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Non-Derivative Transaction:
Security Title:
Value:  Common Stock
Footnote ID:  F3
Transaction Date:
Value:  5/24/22
Deemed Execution Date:
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  D
Equity Swap Involved?  No
Footnote ID:  F1
Footnote ID:  F2
Transaction Timeliness:
Value:
Transaction Amounts:
Transaction Shares:
Value:  49,425
Transaction Price Per Share:
Value:  5.60
Transaction Acquired-Disposed Code:
Value:  D
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  0
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Derivative Table:
Derivative Transaction:
Security Title:
Value:  Stock Option (right to buy)
Conversion or Exercise Price:
Value:  4.54
Transaction Date:
Value:  5/24/22
Deemed Execution Date:
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  D
Equity Swap Involved?  No
Transaction Timeliness:
Value:
Transaction Amounts:
Transaction Shares:
Value:  20,000
Transaction Price Per Share:
Footnote ID:  F4
Transaction Acquired-Disposed Code:
Value:  D
Exercise Date:
Footnote ID:  F4
Expiration Date:
Footnote ID:  F4
Underlying Security:
Underlying Security Title:
Value:  Common Stock
Underlying Security Shares:
Value:  20,000
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  0
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Derivative Transaction:
Security Title:
Value:  Stock Option (right to buy)
Conversion or Exercise Price:
Value:  3.09
Transaction Date:
Value:  5/24/22
Deemed Execution Date:
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  D
Equity Swap Involved?  No
Transaction Timeliness:
Value:
Transaction Amounts:
Transaction Shares:
Value:  61,930
Transaction Price Per Share:
Footnote ID:  F4
Transaction Acquired-Disposed Code:
Value:  D
Exercise Date:
Footnote ID:  F4
Expiration Date:
Footnote ID:  F4
Underlying Security:
Underlying Security Title:
Value:  Common Stock
Underlying Security Shares:
Value:  61,930
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  0
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Derivative Transaction:
Security Title:
Value:  Stock Option (right to buy)
Conversion or Exercise Price:
Value:  2.18
Transaction Date:
Value:  5/24/22
Deemed Execution Date:
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  D
Equity Swap Involved?  No
Transaction Timeliness:
Value:
Transaction Amounts:
Transaction Shares:
Value:  99,395
Transaction Price Per Share:
Footnote ID:  F4
Transaction Acquired-Disposed Code:
Value:  D
Exercise Date:
Footnote ID:  F4
Expiration Date:
Footnote ID:  F4
Underlying Security:
Underlying Security Title:
Value:  Common Stock
Underlying Security Shares:
Value:  99,395
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  0
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Derivative Transaction:
Security Title:
Value:  Stock Option (right to buy)
Conversion or Exercise Price:
Value:  1.12
Transaction Date:
Value:  5/24/22
Deemed Execution Date:
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  D
Equity Swap Involved?  No
Transaction Timeliness:
Value:
Transaction Amounts:
Transaction Shares:
Value:  150,000
Transaction Price Per Share:
Footnote ID:  F4
Transaction Acquired-Disposed Code:
Value:  D
Exercise Date:
Footnote ID:  F4
Expiration Date:
Footnote ID:  F4
Underlying Security:
Underlying Security Title:
Value:  Common Stock
Underlying Security Shares:
Value:  150,000
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  0
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Derivative Transaction:
Security Title:
Value:  Stock Option (right to buy)
Conversion or Exercise Price:
Value:  2.66
Transaction Date:
Value:  5/24/22
Deemed Execution Date:
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  D
Equity Swap Involved?  No
Transaction Timeliness:
Value:
Transaction Amounts:
Transaction Shares:
Value:  80,318
Transaction Price Per Share:
Footnote ID:  F4
Transaction Acquired-Disposed Code:
Value:  D
Exercise Date:
Footnote ID:  F4
Expiration Date:
Footnote ID:  F4
Underlying Security:
Underlying Security Title:
Value:  Common Stock
Underlying Security Shares:
Value:  80,318
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  0
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Derivative Transaction:
Security Title:
Value:  Stock Option (right to buy)
Conversion or Exercise Price:
Value:  2.70
Transaction Date:
Value:  5/24/22
Deemed Execution Date:
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  D
Equity Swap Involved?  No
Transaction Timeliness:
Value:
Transaction Amounts:
Transaction Shares:
Value:  76,548
Transaction Price Per Share:
Footnote ID:  F4
Transaction Acquired-Disposed Code:
Value:  D
Exercise Date:
Footnote ID:  F4
Expiration Date:
Footnote ID:  F4
Underlying Security:
Underlying Security Title:
Value:  Common Stock
Underlying Security Shares:
Value:  76,548
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  0
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Derivative Transaction:
Security Title:
Value:  Stock Option (right to buy)
Conversion or Exercise Price:
Value:  2.92
Transaction Date:
Value:  5/24/22
Deemed Execution Date:
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  D
Equity Swap Involved?  No
Transaction Timeliness:
Value:
Transaction Amounts:
Transaction Shares:
Value:  46,729
Transaction Price Per Share:
Footnote ID:  F4
Transaction Acquired-Disposed Code:
Value:  D
Exercise Date:
Footnote ID:  F4
Expiration Date:
Footnote ID:  F4
Underlying Security:
Underlying Security Title:
Value:  Common Stock
Underlying Security Shares:
Value:  46,729
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  0
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Derivative Transaction:
Security Title:
Value:  Stock Option (right to buy)
Conversion or Exercise Price:
Value:  2.73
Transaction Date:
Value:  5/24/22
Deemed Execution Date:
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  D
Equity Swap Involved?  No
Transaction Timeliness:
Value:
Transaction Amounts:
Transaction Shares:
Value:  58,246
Transaction Price Per Share:
Footnote ID:  F4
Transaction Acquired-Disposed Code:
Value:  D
Exercise Date:
Footnote ID:  F4
Expiration Date:
Footnote ID:  F4
Underlying Security:
Underlying Security Title:
Value:  Common Stock
Underlying Security Shares:
Value:  58,246
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  0
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Derivative Transaction:
Security Title:
Value:  Stock Option (right to buy)
Conversion or Exercise Price:
Value:  4.42
Transaction Date:
Value:  5/24/22
Deemed Execution Date:
Transaction Coding:
Transaction Form Type:  4
Transaction Code:  D
Equity Swap Involved?  No
Transaction Timeliness:
Value:
Transaction Amounts:
Transaction Shares:
Value:  48,542
Transaction Price Per Share:
Footnote ID:  F4
Transaction Acquired-Disposed Code:
Value:  D
Exercise Date:
Footnote ID:  F4
Expiration Date:
Footnote ID:  F4
Underlying Security:
Underlying Security Title:
Value:  Common Stock
Underlying Security Shares:
Value:  48,542
Post-Transaction Amounts:
Shares Owned Following Transaction:
Value:  0
Ownership Nature:
Direct or Indirect Ownership:
Value:  D
Footnotes:
Footnote - F1:  This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").
Footnote - F2:  (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Footnote - F3:  Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.
Footnote - F4:  Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.
Remarks:
Owner Signature:
Signature Name:  /s/ Lisa M. Kallebo as attorney-in-fact for Robert P. Roche Jr.
Signature Date:  5/26/22


↑Top
Filing Submission 0000899243-22-019797   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Mon., May 6, 3:40:40.1am ET